Join ASTCT and CIBMTR for the latest research, emerging therapies, and advances in transplantation and cellular therapy.
📍 Orlando, FL | 📅 Feb. 17-20, 2027
Register: www.tandemmeetings.com/Registration...
Join ASTCT and CIBMTR for the latest research, emerging therapies, and advances in transplantation and cellular therapy.
📍 Orlando, FL | 📅 Feb. 17-20, 2027
Register: www.tandemmeetings.com/Registration...
Fertility preservation in 2026: Current landscape in Europe and the United States for children and adolescents undergoing HCT-recommendations on behalf of the Westhafen Intercontinental Group
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42120917/
Fertility preservation in 2026: Current landscape in Europe and the United States for children and adolescents undergoing HCT-recommendations on behalf of the Westhafen Intercontinental Group
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42120917/
Haploidentical versus HLA-matched unrelated donors for HCT in acute leukemia
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42323086/
Haploidentical versus HLA-matched unrelated donors for HCT in acute leukemia
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42323086/
@astct.bsky.social
@astct.bsky.social
Access challenges in alloHCT: Identifying at-risk US states by exploring social vulnerability, physician density, and unmet need
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42372215/
Access challenges in alloHCT: Identifying at-risk US states by exploring social vulnerability, physician density, and unmet need
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42372215/
Classical HLA allele and haplotype frequency estimates in US populations
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42341485/
Classical HLA allele and haplotype frequency estimates in US populations
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42341485/
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42416786/
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42416786/
Join ASTCT and CIBMTR in Orlando, February 17-20, 2027, for the premier event in HCT, cellular therapy, and gene therapy.
📍 Orlando, FL
📅 February 17-20, 2027
Secure your spot today: www.tandemmeetings.com/Registration...
Join ASTCT and CIBMTR in Orlando, February 17-20, 2027, for the premier event in HCT, cellular therapy, and gene therapy.
📍 Orlando, FL
📅 February 17-20, 2027
Secure your spot today: www.tandemmeetings.com/Registration...
Don't miss your chance to shape future research. There's only 1 week left to submit a proposal for consideration for a CIBMTR Working Committee study.
📅 Deadline: Monday, Sept. 21
🔗cibmtr.org/CIBMTR/Resea...
Don't miss your chance to shape future research. There's only 1 week left to submit a proposal for consideration for a CIBMTR Working Committee study.
📅 Deadline: Monday, Sept. 21
🔗cibmtr.org/CIBMTR/Resea...
Infection burden in mismatched unrelated donor HCT: Results from the ACCESS Trial
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42448319/
Infection burden in mismatched unrelated donor HCT: Results from the ACCESS Trial
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42448319/
CIBMTR is accepting Working Committee Study proposals from investigators interested in leading impactful observational research.
📅 Deadline: Monday, Sept. 21
Submit today: cibmtr.org/CIBMTR/Resea...
CIBMTR is accepting Working Committee Study proposals from investigators interested in leading impactful observational research.
📅 Deadline: Monday, Sept. 21
Submit today: cibmtr.org/CIBMTR/Resea...
Submit a CIBMTR Working Committee study proposal for consideration at the 2027 Tandem Meetings.
📅 Deadline: Monday, Sept. 21
🔗 cibmtr.org/CIBMTR/Resea...
Submit a CIBMTR Working Committee study proposal for consideration at the 2027 Tandem Meetings.
📅 Deadline: Monday, Sept. 21
🔗 cibmtr.org/CIBMTR/Resea...
@astct.bsky.social
@astct.bsky.social
@astct.bsky.social
@astct.bsky.social
Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in AML in first complete remission: CIBMTR analysis
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42206435/
Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in AML in first complete remission: CIBMTR analysis
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42206435/
IMPACT for patients with inborn errors of immunity from the Primary Immune Deficiency Treatment Consortium
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42242424/
IMPACT for patients with inborn errors of immunity from the Primary Immune Deficiency Treatment Consortium
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42242424/
Comparison of fludarabine versus bendamustine as a lymphodepleting chemotherapy prior to CAR T for large cell lymphoma
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42341926/
Comparison of fludarabine versus bendamustine as a lymphodepleting chemotherapy prior to CAR T for large cell lymphoma
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42341926/
The August 2026 Newsletter is here! Explore research highlights from our working committees, updates on adoptive cellular therapies & gene therapy reporting, 2025 US Summary Slides, and a preview of #Tandem27. 📬
cibmtr.org/CIBMTR/About...
The August 2026 Newsletter is here! Explore research highlights from our working committees, updates on adoptive cellular therapies & gene therapy reporting, 2025 US Summary Slides, and a preview of #Tandem27. 📬
cibmtr.org/CIBMTR/About...
CIBMTR 報告:初始 CR 率 85.5%,12 個月的反應持續 60.9%、EFS 52.4%、OS 77.2%。
CRS 發生率 55%,其中 ≥3 級佔 16.1%,處置以 tocilizumab 與類固醇為主。
關鍵:達到緩解後「只有少數」接續移植 —— 說 90% 都去移植是錯的,CAR-T 本身即具治癒意圖。
#血液專科
https://hema-2026.hsiehting.com/q/110-076
CIBMTR 報告:初始 CR 率 85.5%,12 個月的反應持續 60.9%、EFS 52.4%、OS 77.2%。
CRS 發生率 55%,其中 ≥3 級佔 16.1%,處置以 tocilizumab 與類固醇為主。
關鍵:達到緩解後「只有少數」接續移植 —— 說 90% 都去移植是錯的,CAR-T 本身即具治癒意圖。
#血液專科
https://hema-2026.hsiehting.com/q/110-076
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR analysis
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42364732/
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR analysis
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42364732/
Quantile regression of the relationship between demographic factors and leukocyte telomere length, measured by Southern blot and qPCR Read more:
🔗pubmed.ncbi.nlm.nih.gov/41619133/
Quantile regression of the relationship between demographic factors and leukocyte telomere length, measured by Southern blot and qPCR Read more:
🔗pubmed.ncbi.nlm.nih.gov/41619133/